Pennant Investors, LP Allogene Therapeutics, Inc. Transaction History
Pennant Investors, LP
- $367 Million
- Q2 2024
A detailed history of Pennant Investors, LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Pennant Investors, LP holds 128,400 shares of ALLO stock, worth $338,976. This represents 0.08% of its overall portfolio holdings.
Number of Shares
128,400
Previous 128,400
-0.0%
Holding current value
$338,976
Previous $573,000
47.82%
% of portfolio
0.08%
Previous 0.14%
Shares
1 transactions
Others Institutions Holding ALLO
# of Institutions
175Shares Held
132MCall Options Held
94.3KPut Options Held
112K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$49.4 Million1.08% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$43.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$21.6 Million0.0% of portfolio
-
State Street Corp Boston, MA7.67MShares$20.2 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$18.2 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $380M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...